GlassScriptPhysician profile
Bradley Glodny
NPI 1326347766
$65,020.07
in general payments reported to CMS, 2019-2025
43 companies · $8,340 in 2025
The $8,340 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,428 · 2020: $1,223 · 2021: $1,344 · 2022: $10K · 2023: $28K · 2024: $14K · 2025: $8,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $7,426 · Consulting Fee: $1,290 · Education: $322 · Travel and Lodging: $75.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,814.04 |
| Food and Beverage | $7,425.78 |
| Consulting Fee | $1,290.00 |
| Education | $321.92 |
| Travel and Lodging | $75.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $46,810.47 | 2019-2025 | Aklief, Epsolay, Oracea |
| Fidia Pharma USA INC. | $5,127.26 | 2024-2025 | Hymovis |
| Abbvie INC. | $2,088.46 | 2019-2025 | |
| Incyte Corporation | $2,038.99 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $858.43 | 2019-2025 | Tremfya |
| Pfizer INC. | $806.69 | 2019-2025 | |
| Genzyme Corporation | $779.87 | 2019-2025 | |
| Allergan, INC. | $776.04 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $716.32 | 2019-2025 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $635.30 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $549.63 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $493.73 | 2019-2025 | Cabtreo |
| Regeneron Healthcare Solutions, INC. | $361.49 | 2019-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $295.94 | 2023-2025 | Zoryve |
| Almirall LLC | $280.67 | 2021-2025 | Klisyri |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Glodny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.